Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT03911388Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2019
- Primary completion
- Sep 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of G207 in brain tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events. Started Sep 2019; status: recruiting.
02
Drugs
G207
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT03911388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911388.